5-Lipoxygenase:: Regulation and possible involvement in atherosclerosis

被引：64
|
作者：
Radmark, Olof [1 ]
Samuelsson, Bengt [1 ]
机构：
[1] Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden
来源：
PROSTAGLANDINS & OTHER LIPID MEDIATORS | 2007年 / 83卷 / 03期
关键词：
leukotriene; eicosanoid; arachidonic acid; inflammation;
D O I：
10.1016/j.prostaglandins.2007.01.003
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
This review article focuses on two aspects regarding 5-lipoxygenase. First, mechanisms for activation of the enzyme. Second, the involvement of 5-lipoxygenase and leukotrienes in atherosclerosis. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码：162 / 174
页数：13
相关论文
共 50 条
  • [31] Interaction between nitric oxide, reactive oxygen intermediates, and peroxynitrite in the regulation of 5-lipoxygenase metabolism
    Coffey, MJ
    Phare, SM
    Peters-Golden, M
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2002, 1584 (2-3): : 81 - 90
  • [32] On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance
    Siemoneit, Ulf
    Pergola, Carlo
    Jazzar, Bianca
    Northoff, Hinnak
    Skarke, Carsten
    Jauch, Johann
    Werz, Oliver
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 606 (1-3) : 246 - 254
  • [33] 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity
    Fischer, A. S.
    Metzner, J.
    Steinbrink, S. D.
    Ulrich, S.
    Angioni, C.
    Geisslinger, G.
    Steinhilber, D.
    Maier, T. J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (04) : 936 - 949
  • [34] Interaction of 5-lipoxygenase with cellular proteins
    Provost, P
    Samuelsson, B
    Rådmark, O
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) : 1881 - 1885
  • [35] Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126
    Stewart, LR
    White, AR
    Jobling, MF
    Needham, BE
    Maher, F
    Thyer, J
    Beyreuther, K
    Masters, CL
    Collins, SJ
    Cappai, R
    JOURNAL OF NEUROSCIENCE RESEARCH, 2001, 65 (06) : 565 - 572
  • [36] 5-lipoxygenase inhibitors for the treatment of COPD
    Kilfeather, S
    CHEST, 2002, 121 (05) : 197S - 200S
  • [37] Recent developments in 5-lipoxygenase inhibitors
    Julémont, F
    Dogné, JM
    Laeckmann, D
    Pirotte, B
    de Leval, X
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (01) : 1 - 13
  • [38] A mutation interfering with 5-lipoxygenase domain interaction leads to increased enzyme activity
    Ryge, Marija Rakonjac
    Tanabe, Michiharu
    Provost, Patrick
    Persson, Bengt
    Chen, Xinsheng
    Funk, Colin D.
    Rinaldo-Matthis, Agnes
    Hofmann, Bettina
    Steinhilber, Dieter
    Watanabe, Takashi
    Samuelsson, Bengt
    Radmark, Olof
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 545 : 179 - 185
  • [39] A selective inhibitor of arachidonate 5-lipoxygenase scavenging peroxide activator
    Suzuki, H
    Miyauchi, D
    Yamamoto, S
    BIOCHEMICAL PHARMACOLOGY, 1997, 54 (04) : 529 - 532
  • [40] The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease
    Poeckel, Daniel
    Funk, Colin D.
    CARDIOVASCULAR RESEARCH, 2010, 86 (02) : 243 - 253
12345